Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

291 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al. Schnur RC, et al. Among authors: cooper ba. J Med Chem. 1995 Sep 15;38(19):3806-12. doi: 10.1021/jm00019a010. J Med Chem. 1995. PMID: 7562911
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F. Roberts WG, et al. Cancer Res. 2008 Mar 15;68(6):1935-44. doi: 10.1158/0008-5472.CAN-07-5155. Cancer Res. 2008. PMID: 18339875
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.
Munchhof MJ, Beebe JS, Casavant JM, Cooper BA, Doty JL, Higdon RC, Hillerman SM, Soderstrom CI, Knauth EA, Marx MA, Rossi AM, Sobolov SB, Sun J. Munchhof MJ, et al. Among authors: cooper ba. Bioorg Med Chem Lett. 2004 Jan 5;14(1):21-4. doi: 10.1016/j.bmcl.2003.10.030. Bioorg Med Chem Lett. 2004. PMID: 14684289
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, Cooper BA, Kath JC, Hulford CA, Autry CL, Luzzio MJ, Ung EJ, Roberts WG, Bonnette PC, Buckbinder L, Mistry A, Griffor MC, Han S, Guzman-Perez A. Walker DP, et al. Among authors: cooper ba. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6071-7. doi: 10.1016/j.bmcl.2008.10.030. Epub 2008 Oct 11. Bioorg Med Chem Lett. 2008. PMID: 18951788
erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.
Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, DiOrio CI, Barbacci EG, Miller PE, et al. Schnur RC, et al. Among authors: cooper ba. J Med Chem. 1995 Sep 15;38(19):3813-20. doi: 10.1021/jm00019a011. J Med Chem. 1995. PMID: 7562912
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E. Roberts WG, et al. Cancer Res. 2005 Feb 1;65(3):957-66. Cancer Res. 2005. PMID: 15705896
Cellular characterization of a novel focal adhesion kinase inhibitor.
Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. Slack-Davis JK, et al. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28. J Biol Chem. 2007. PMID: 17395594
Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study.
Ethier I, Cho Y, Hawley C, Pascoe EM, Viecelli AK, Campbell SB, van Eps C, Isbel NM, Cooper BA, Harris DC, Pollock CA, Wong MG, Johnson DW. Ethier I, et al. Among authors: cooper ba. PLoS One. 2020 Nov 16;15(11):e0242254. doi: 10.1371/journal.pone.0242254. eCollection 2020. PLoS One. 2020. PMID: 33196667 Free PMC article.
Distinct diarrhea profiles during outpatient chemotherapy.
Diaz R, Kober KM, Viele C, Cooper BA, Paul SM, Hammer M, Wright F, Conley YP, Levine JD, Miaskowski C. Diaz R, et al. Among authors: cooper ba. Support Care Cancer. 2020 Sep 12. doi: 10.1007/s00520-020-05753-x. Online ahead of print. Support Care Cancer. 2020. PMID: 32918132
Co-occurrence of decrements in physical and cognitive function is common in older oncology patients receiving chemotherapy.
Utne I, Cooper BA, Ritchie C, Wong M, Dunn LB, Loyland B, Grov EK, Hammer MJ, Paul SM, Levine JD, Conley YP, Kober KM, Miaskowski C. Utne I, et al. Among authors: cooper ba. Eur J Oncol Nurs. 2020 Oct;48:101823. doi: 10.1016/j.ejon.2020.101823. Epub 2020 Aug 3. Eur J Oncol Nurs. 2020. PMID: 32835999
291 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback